Desjardins, A., Vredenburgh, J. J., Peters, K. B., Threatt, S., Herndon, J. E., Sampson, J. H., … Reardon, D. A. (2012). Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Desjardins, Annick, James J. Vredenburgh, Katherine B. Peters, Stevie Threatt, James Emmett Herndon, John Howard Sampson, Allan H. Friedman, Henry S. Friedman, and David A. Reardon. “Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Desjardins A, Vredenburgh JJ, Peters KB, Threatt S, Herndon JE, Sampson JH, et al. Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.

Desjardins, Annick, et al. “Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.

Desjardins A, Vredenburgh JJ, Peters KB, Threatt S, Herndon JE, Sampson JH, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.